By SPC News Staff
The FDA approved anifrolumab-fnia (Saphnelo, AstraZeneca), a first-in-class treatment for adults with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
This marks the first regulatory approval for a type I interferon (type I IFN) receptor antagonist and the only new treatment approved for SLE in more than 10 years. Type I IFN plays a central role in the pathophysiology of lupus. Increased type I IFN signaling is associated with increased